论文部分内容阅读
目的探析培美曲塞联合顺铂与吉西他滨联合顺铂在非小细胞肺癌治疗中的临床效果。方法 74例非小细胞肺癌患者为本次研究对象,随机分为对照组及观察组,各37例。对照组采用吉西他滨+顺铂的方式进行治疗,观察组采用培美曲塞+顺铂的方式进行治疗。以3周为1个周期,2个周期治疗后,对比两组疗效。结果对照组总有效率为43.24%,观察组总有效率为40.54%,对比差异无统计学意义(χ2=0.056,P>0.05)。观察组毒副反应发生率48.65%低于对照组78.38%,差异具有统计学意义(χ2=7.056,P<0.05)。结论在非小细胞肺癌的临床治疗中,培美曲塞联合顺铂与吉西他滨联合顺铂均能够取得较为理想的治疗效果,但培美曲塞联合顺铂的治疗方式则能够有效减少毒副反应发生率,因而在临床治疗上具有更高的应用价值。
Objective To investigate the clinical effect of pemetrexed combined with cisplatin and gemcitabine plus cisplatin in the treatment of non-small cell lung cancer. Methods A total of 74 patients with non-small cell lung cancer were randomly divided into control group and observation group, with 37 cases in each group. The control group was treated with gemcitabine + cisplatin, and the observation group was treated with pemetrexed + cisplatin. To 3 weeks for a cycle, two cycles of treatment, the two groups were compared. Results The total effective rate of the control group was 43.24%, the total effective rate of the observation group was 40.54%, the difference was not statistically significant (χ2 = 0.056, P> 0.05). The incidence of adverse reactions in the observation group was 48.65% lower than that in the control group (78.38%), the difference was statistically significant (χ2 = 7.056, P <0.05). Conclusion Pemetrexed combined with cisplatin and gemcitabine combined with cisplatin can achieve satisfactory therapeutic effect in the treatment of non-small cell lung cancer. However, pemetrexed combined with cisplatin can effectively reduce side effects Incidence, and thus in clinical treatment has a higher value.